• Users Online: 482
  • Print this page
  • Email this page
Year : 2021  |  Volume : 23  |  Issue : 3  |  Page : 137-144

Update in treatment of pulmonary sarcoidosis

Department of Pulmonary Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Correspondence Address:
Dr. Elif Babaoglu
Department of Pulmonary Medicine, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ejop.ejop_120_20

Rights and Permissions

Sarcoidosis is a chronic granulomatous multisystem disease with an unknown etiology. The diagnosis of sarcoidosis relies on the presence of noncaseating granuloma on histopathological examination with compatible clinical presentation and exclusion of other causes of granulomatous inflammation. Lungs and intrathoracic lymph nodes are the most commonly affected organs. Most of the patients are asymptomatic. Symptomatic patients generally have spontaneous resolution. 25% of patients have progressive lung disease and 10% of patients have organ failure. Corticosteroids, immunosuppressive, cytotoxic, and antimalarial drugs are used for sarcoidosis treatment. The decision of appropriate treatment is very important. The aim of this review is to summarize the actual treatment of pulmonary sarcoidosis.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded119    
    Comments [Add]    

Recommend this journal